Synaptic plasticity: nootropics and compounds | sci-wiki

N-PEP-12

N-PEP-12 is an oral dietary supplement of small brain-derived peptides and free amino acids, sold as Memoprove and described by its own investigators as a lower-potency, needle-free relative of the injectable neurotrophic drug Cerebrolysin. Small, mostly manufacturer-linked studies report modest short-term gains in memory and brain EEG activity in aging adults and in stroke recovery. It is an appealing, gentle nootropic idea, but the human evidence is thin and largely industry-linked, and the core assumption that oral brain peptides survive digestion to reach the brain remains pharmacologically unproven.

1 outlet

Nootropic

HBT1

HBT1 is a positive allosteric modulator of the AMPA receptor (an "ampakine") that came out of a Takeda drug-discovery program. Its selling point is a gentler profile than earlier ampakines; it has low intrinsic agonist activity and works mostly only when the brain's own glutamate is present, which let it raise BDNF (brain-derived neurotrophic factor, a key growth signal for neurons) in lab neurons without the bell-shaped drop-off and overexcitation that stronger AMPA potentiators tend to cause [1]. It has only been studied in cells and animals, so it remains an experimental research compound rather than an established nootropic.

reference

Nootropic

24(S)-Hydroxycholesterol

24(S)-Hydroxycholesterol (historically named cerebrosterol) is an endogenous oxysterol (an oxygenated derivative of cholesterol) generated almost exclusively in neurons by the enzyme cholesterol 24-hydroxylase (CYP46A1). It is the principal chemical route by which the brain, which cannot degrade cholesterol, exports its surplus; because the added hydroxyl group at carbon 24 allows the molecule to cross the blood-brain barrier (the selective interface between blood and brain tissue), plasma levels of 24(S)-hydroxycholesterol serve as an accessible marker of brain cholesterol turnover and neuronal mass. Beyond its housekeeping role, it is a bona fide neurosteroid; at physiological concentrations it acts as a potent positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors (a class of glutamate-gated ion channels central to learning and memory) and as an agonist of liver X receptors (LXR, nuclear receptors that govern lipid handling). Its pharmacology inspired the synthetic analog dalzanemdor (SAGE-718), an NMDA receptor positive allosteric modulator developed for cognitive impairment.

reference

Nootropic

L-Clausenamide

L-Clausenamide, or (-)-clausenamide, is a pyrrolidinone alkaloid isolated from the leaves of Clausena lansium (wampee) and studied in China as a nootropic and neuroprotective anti-dementia drug candidate [1]. It is the eutomer of the clausenamide enantiomers, improving learning and memory through multi-target actions including modulation of intracellular calcium, cholinergic support, enhancement of synaptic plasticity and long-term potentiation, and antioxidant protection [1]. In cellular and animal models it protects neurons against beta-amyloid, okadaic-acid and ischemic injury and inhibits ferroptosis in dopaminergic neurons [2][3][4].

reference

Neuroprotection

Nitromemantine

Nitromemantine is an experimental, two-in-one derivative of memantine developed largely by Stuart Lipton's group. It keeps memantine's aminoadamantane body, which parks inside overactive NMDA receptor channels (a major glutamate receptor), and bolts on a nitro/nitrate group that acts as a targeted warhead to deliver nitric oxide to a regulatory (redox) site on the same receptor. The idea is to shut down damaging, chronically overactive extrasynaptic NMDA receptors while sparing the normal synaptic signaling the brain needs to learn. It remains a preclinical research compound, studied in cell and animal models of Alzheimer's, autism-linked syndromes, tuberous sclerosis, Parkinson's-type synuclein damage, and depression; it is not an approved drug.

reference

Nootropic

T-817MA

T-817MA, later given the generic name edonerpic maleate, was developed by Toyama Chemical (subsequently absorbed into Fujifilm's pharmaceutical division) as a neurotrophic and neuroprotective small molecule aimed squarely at Alzheimer's disease, but built on a different premise than amyloid-clearing antibodies: promote neurite outgrowth and protect synapses from amyloid-beta toxicity directly. It advanced through multiple Phase II trials in Japan, the US and Europe, including a joint program with the Alzheimer's Disease Cooperative Study, and produced a real biomarker signal, dose-dependent drops in cerebrospinal fluid tau. That biomarker success never translated into a clinical cognitive benefit large enough to justify a Phase III program, and the compound was shelved, joining the long list of tau- and neuroprotection-targeted Alzheimer's candidates that moved the numbers without moving the patient.

reference